IP Library › Patent Application 13930051
Patent Application
App. No. 13/930,051

METHOD OF TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD)

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/930,051
Abstract

The invention comprises a method for treatment of ADHD or ADHD-related disorders by a pharmaceutical agent exhibiting combined serotonergic or noradrenergic reuptake transporters and monoamine receptor activity.

Claims (8)

1 . A method for treatment of ADHD in a human subject in need thereof comprising administering to the subject a therapeutically effective amount of a formulation of viloxazine.

2 . The method of claim 1 , wherein the therapeutically effective amount is from about 10 to about 600 mg a day.

3 . The method of claim 1 , wherein the human subject is a human child.

4 . The method of claim 2 , which provides an improved adverse effect profile.

5 . A method for treatment of ADHD in a human subject in need thereof comprising administering to said subject a therapeutically effective amount of a pharmaceutical agent exhibiting 5HT1B and/or 5HT7 antagonistic activity.

6 . A method for treatment of ADHD in a human subject in need thereof comprising administering to said subject a therapeutically effective amount of a pharmaceutical agent exhibiting combined noradrenergic reuptake inhibitory activity and a 5HT1B or 5HT7 antagonistic activity.

7 . A method for treatment of ADHD in a human subject in need thereof comprising administering to said subject a therapeutically effective amount of a pharmaceutical agent exhibiting combined noradrenergic reuptake inhibitory activity and α 4 /β 2 and/or α7 antagonistic activity.

8 . A method for treatment of ADHD in a human subject in need thereof comprising administering to said subject a therapeutically effective amount of a pharmaceutical agent exhibiting combined 5HT1B and/or 5HT7 antagonistic activity and α 4 /β 2 and/or α7 antagonistic activity.